Onbrez Bryzhaler capsules powder for inhalation 300mkg n30

Composition

Indacaterola maleate

Excipients: lactose monohydrate

Packing

30 pieces

Mechanism of action

ONBREZE BRIZHALER - indacaterol is a selective long-acting β2-adrenoreceptor agonist (for 24 hours) in a single dose. The pharmacological action of β2-adrenoreceptor agonists, including indacaterol, is associated with the stimulation of intracellular adenylate cyclase, an enzyme that catalyzes the conversion of ATP to cyclic 3 ', 5'-adenosine monophosphate (cyclic AMP). Increasing the content of cyclic AMP leads to relaxation of the smooth muscles of the bronchi. Indacaterol is a nearly complete β2-adrenoreceptor agonist; The stimulating effect of the drug on β2-adrenoreceptors is 24 times stronger than on β1-adrenergic receptors, and 20 times stronger than β3-adrenergic receptors.

After inhalation, the drug has a rapid and prolonged bronchodilatory effect.

Indacaterol provides sustained significant improvement in lung function (increased forced expiratory volume in the first second, FEV1) for 24 hours. The drug is characterized by a rapid onset of action (within 5 minutes after inhalation), comparable to the effect of Salbutamol, a short-acting β2-adrenoreceptor agonist. The maximum effect of indacaterol is noted 2-4 hours after inhalation.In patients who received indacaterol for 1 year, there was no development of tachyphylaxis to the bronchodilatory effect of the drug. When using indacaterol, there was no dependence of the bronchodilating effect on the time of inhalation of the drug during the day (in the morning or in the evening).

Indacaterol reduces dynamic and static hyperinflation (an increase in lung volumes at the end of spontaneous expiration) in patients with moderate and severe COPD. When using the drug there is a statistically significant increase in inspiratory capacity and FEV1, a decrease in shortness of breath, and an improvement in exercise tolerance. There is also a significant reduction in the risk of COPD exacerbations (an increase in time until the next exacerbation), a reduction in the need for short-acting β2-adrenoreceptor inhalation agonists and an improvement in the quality of life of patients (assessed using a certified questionnaire at St. George's Hospital).

Indications and usage

Long-term maintenance therapy of bronchial obstruction in patients with COPD.

Contraindications

- age up to 18 years (efficiency and safety have not been established);

- pregnancy;

- breastfeeding period;

- Hypersensitivity to any of the components of the drug.

Dosage and administration

For inhalation use only!

The drug is a capsule with powder for inhalation, which should be used only for inhalation through the mouth using a special device - Brizhalera, which is included in the kit. The drug can not be taken orally.Capsules with powder for inhalation should be stored in a blister and removed from it immediately before use. Inhalation of the drug is carried out daily 1 time / day at the same time. In the case of inhalation, the next day Onbrez® Brizhaler® is used at the usual time.

The recommended dose of the drug is 150 mcg (1 capsule 150 mcg contents) 1 time / day (1 inhalation per day). The dose of the drug can be increased only on the recommendation of a doctor.

Inhalation of the drug at a dose of 300 mcg (the contents of 1 capsule 300 mcg) 1 time / day may provide additional clinical effect in some patients, for example, in patients with severe COPD.

The maximum dose - 300 mcg (contents of 1 capsule 300 mcg) 1 time / day (1 inhalation per day). The maximum allowable dose of the drug can not be exceeded.

Dosage adjustment of the drug is not required in patients aged 65 and older, patients with mild and moderate hepatic and renal dysfunction.

Storage conditions

At a temperature not higher than 30 ° C.